| Literature DB >> 32342165 |
Bernadette Maria Theresia Kriechenbauer1, Tobias Franiel1, Florian Bürckenmeyer1, René Aschenbach1, Ioannis Diamantis1, Amer Malouhi1, Beatrice Steiniger1, Ulf Teichgräber2,3.
Abstract
PURPOSE: To assess radiation exposure in men undergoing prostate artery embolization (PAE) for the treatment for symptomatic, benign prostatic hyperplasia depending on growing experience of interventional radiologists over a 4-year period.Entities:
Keywords: Cone beam computed tomography; Embolization; Lower urinary tract symptoms; Prostatic hyperplasia; Radiation exposure; therapeutic
Mesh:
Year: 2020 PMID: 32342165 PMCID: PMC7369265 DOI: 10.1007/s00270-020-02461-1
Source DB: PubMed Journal: Cardiovasc Intervent Radiol ISSN: 0174-1551 Impact factor: 2.740
Patient baseline characteristics
| Age, years ( | 68.9 (11.7) |
| Body mass index, kg/m2 ( | 26.5 (5.3) |
| Peak urinary flow, ml/s ( | 9.2 (5.7) |
| Micturition volume, ml ( | 173 (127) |
| Time of micturition, s ( | 44 (37) |
| Post-void residual, ml ( | 60 (80) |
| Urinary catheter ( | 14 (5.6) |
| PSA, ng/ml ( | 2.99 (3.26) |
| Prostate volumea, cm3 ( | 60 (37) |
| Prostate artery > 1 | |
| Right | 4/250 (1.6) |
| Left | 6/250 (2.4) |
| IIEF-5 score, 1 to 25 ( | 16 (15) |
| IIEF-EF score, 1 to 30 ( | 20 (17) |
| IPSS score, 0 to 35 ( | 23 (9) |
| QoL (IPSS question 8), 0 to 6 ( | 5 (1) |
Continuous values are presented as median (interquartile range) and categorical values as counts (percentage)
IIEF international index of erectile function, IPSS international prostate symptom score, PSA prostate- specific antigen, QoL quality of life
aDetermined by transrectal ultrasound or magnetic resonance tomography
Body mass index and lower urinary tract symptoms across consecutive patient groups
| Group I | Group II | Group III | Group IV | Group V | ||
|---|---|---|---|---|---|---|
| Body mass index, kg/m2 | 27.1 (5.4) | 27.1 (6.3) | 25.8 (3.5) | 26.5 (3.5) | 25.4 (5.2) | |
| Prostate volume, cm3 | 60 (57) | 60 (39) | 65 (30) | 60 (40) | 57 (40) | |
| Peak urinary flow, ml/s | 8.7 (8.6) | 9.8 (5.1) | 9.1 (6.3) | 9.9 (6.0) | 9.0 (5.7) | |
| Micturition volume, ml | 151 (189) | 213 (143) | 158 (120) | 159 (140) | 175 (118) | |
| Time of micturition, s | 33 (27) | 45 (39) | 40 (37) | 47 (43) | 44 (34) | |
| Post-void residual, ml | 50 (65) | 59 (81) | 70 (83) | 60 (97) | 80 (100) |
Values are presented as median (interquartile range)
Radiation exposure and procedure characteristics of five consecutive patient cohorts who underwent prostate artery embolization
| Group I | Group II (51–100) | Group III (101–150) | Group IV (151–200) | Group V (201–250) | |||||
|---|---|---|---|---|---|---|---|---|---|
| DAP, μGym2 | 56 298 (36 852) | 24 709 (34 427) | 27 937 (15 875) | 25 957 (25 036) | 20 942 (18 829) | ||||
| ED, mSv | 146.4 (95.8) | 64.2 (89.5) | 72.6 (41.3) | 67.5 (65.1) | 54.4 (49.0) | ||||
| ESD, Gy | 5.1 (3.6) | 2.4 (2.8) | 2.5 (2.2) | 2.4 (2.0) | 2.2 (2.3) | ||||
| CBCT conducted | 46 (92%) | 50 (100%) | 40 (80%) | 33 (66%) | 33 (66%) | ||||
| Series of DSA, no | 28 (15) | 24 (14) | 23 (13) | 20 (11) | 20 (8) | ||||
| DAP from 2D- mode, %e | 82 (14) | 72 (30) | 77 (20) | 80 (33) | 75 (43) | ||||
| ESD from 2D-mode, %e | 93 (5) | 90 (13) | 92 (9) | 94 (11) | 92 (17) | ||||
| Fluoroscopy time, min | 38 (32) | 30 (31) | 29 (19) | 25 (26) | 24 (24) | ||||
| Procedure time, min | 175 (71) | 128 (62) | 110 (60) | 97 (61) | 100 (46) | ||||
| Contrast medium, ml | 110 (70) | 120 (50) | 110 (40) | 100 (56) | 100 (30) | ||||
| Bilateral PAE | 41 (82%) | 42 (84%) | 36 (72%) | 39 (78%) | 43 (86%) |
Values are presented as median (interquartile range), categorical values as counts (percentage)
CBCT cone beam computed tomography; DAP dose area product; DSA digital subtraction angiography; ED effective dose; ESD entrance skin dose
ap values apply to group I versus group II, b to group II versus group III, c to group III versus group IV, d to group IV versus group V, e also patients without CBCT included
Fig. 1Association of DAP with selected variables evaluated by linear regression adjusted for random effect of individual radiologists. Regression coefficient represents the mean change in DAP for one unit of change in the predictive variable or for switching from one category of the predictive variable to the other. BMI body mass index, CBCT cone beam computed tomography, DAP dose area product, PAE prostate artery embolization
Fig. 2Dose area product (A), entrance skin dose (B), in consecutive patients who underwent prostate artery embolization over a 4-year period. Linear regression fits a line through data points, and Pearson correlation (r) describes the strength of the relationship between number of patients treated so far and the respective dependent variable
Fig. 3Number of DSA series (A), fluoroscopy time (B), and procedure time (C) in consecutive patients who underwent prostate artery embolization over a 4-year period. Linear regression fits a line through data points, and Pearson correlation (r) describes the strength of the relationship between number of patients treated so far and the respective dependent variable. DSA digital subtraction angiography
Radiation exposure and procedure characteristics depending on accomplished embolization
| Total cohort | Bilateral embolization | Unilateral embolization | Failed embolization | ||
|---|---|---|---|---|---|
| Procedures | 250 (100%) | 201 (80.4%) | 47 (18.8%) | 2 (0.8%) | |
| DAP, μGym2 | 28 612 (31 416) | 27 636 (30 199) | 34 786 (36 656) | 52,093 | |
| ED, mSv | 74.4 (81.7) | 71.9 (78.5) | 90.4 (95.3) | 135.4 | |
| ESD, Gy | 2.7 (2.8) | 2.5 (2.6) | 3.5 (3.2) | 5.4 | |
| Fluoroscopy time, min | 28 (25) | 26 (24) | 42 (29) | 50 | |
| Series of DSA, no | 23 (3) | 22 (12) | 28 (18) | 30 | |
| Procedure time, min | 120 (70) | 110 (74) | 146 (60) | 260 | |
| Contrast medium, ml | 111 (40) | 105 (40) | 120 (60) | 133 |
Continuous values are presented as median (interquartile range) and categorical values as counts (percentage)
DAP dose area product, DSA digital subtraction angiography, ED effective dose, ESD entrance skin dose